Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial

Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial

Abstract Background MYC genes regulate ornithine decarboxylase (Odc) to increase intratumoral polyamines. We conducted a Phase I trial [NCT02030964] to determine the maximum tolerated dose (MTD) of DFMO, an Odc inhibitor, with celecoxib, cyclophosphamide and topotecan. Methods Patients 2–30 years of...

Olles dieđut

Furkejuvvon:
Bibliográfalaš dieđut
Váldodahkkit: Michael D. Hogarty, David S. Ziegler, Andrea Franson, Yueh‐Yun Chi, Denice Tsao‐Wei, Kangning Liu, Rohan Vemu, Eugene W. Gerner, Elizabeth Bruckheimer, Anasheh Shamirian, Beth Hasenauer, Frank M. Balis, Susan Groshen, Murray D. Norris, Michelle Haber, Julie R. Park, Katherine K. Matthay, Araz Marachelian
Materiálatiipa: Artigo
Giella:eaŋgalasgiella
Almmustuhtton: 2024
Liŋkkat:https://doi.org/10.1038/s41416-023-02525-2
https://www.nature.com/articles/s41416-023-02525-2.pdf
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Interneahtta

https://doi.org/10.1038/s41416-023-02525-2
https://www.nature.com/articles/s41416-023-02525-2.pdf

Geahča maid